1. Home
  2. ASPI vs FTRE Comparison

ASPI vs FTRE Comparison

Compare ASPI & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASPI

ASP Isotopes Inc.

HOLD

Current Price

$6.55

Market Cap

1.0B

Sector

Industrials

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$16.48

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASPI
FTRE
Founded
2021
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.3B
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
ASPI
FTRE
Price
$6.55
$16.48
Analyst Decision
Strong Buy
Buy
Analyst Count
2
9
Target Price
$12.00
$14.06
AVG Volume (30 Days)
5.8M
1.1M
Earning Date
04-10-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$23,849,000.00
$2,723,400,000.00
Revenue This Year
$68.41
N/A
Revenue Next Year
$126.69
$3.09
P/E Ratio
N/A
N/A
Revenue Growth
475.48
1.00
52 Week Low
$3.92
$4.46
52 Week High
$14.49
$18.67

Technical Indicators

Market Signals
Indicator
ASPI
FTRE
Relative Strength Index (RSI) 51.16 63.11
Support Level $4.84 $15.66
Resistance Level $8.41 $18.08
Average True Range (ATR) 0.76 1.09
MACD -0.16 0.05
Stochastic Oscillator 30.72 78.80

Price Performance

Historical Comparison
ASPI
FTRE

About ASPI ASP Isotopes Inc.

ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

Share on Social Networks: